It was evident that expression of FASN is commensurate with the tumor's grade and resistance to therapeutic agents such as tamoxifen (estrogen receptor antagonists), as observed in endocrine therapy in ER+ breast cancer. This evidence concerns the gene FASN and breast carcinoma.